The American Journal of Medicine
Volume 120, Issue 7 , Pages 616-622 , July 2007

C-Reactive Protein and Heart Failure after Myocardial Infarction in the Community

  • Francesca Bursi, MD, MSc

      Affiliations

    • Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minn
    • ,
  • Susan A. Weston, MS

      Affiliations

    • Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minn.
    • ,
  • Jill M. Killian, BS

      Affiliations

    • Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minn.
    • ,
  • Sherine E. Gabriel, MD, MSc

      Affiliations

    • Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minn.
    • ,
  • Steven J. Jacobsen, MD, PhD

      Affiliations

    • Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minn.
    • ,
  • Véronique L. Roger, MD, MPH

      Affiliations

    • Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minn
    • Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minn.
    • Corresponding Author InformationRequests for reprints should be addressed to Véronique L. Roger, MD, MPH, Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55901.

References 

  1. Roger VL, Jacobsen SJ, Weston SA, et al. Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. [summary for patients in Ann Intern Med. 2002;136(5):I16; PMID: 11874327] Ann Intern Med. 2002;136(5):341–348
  2. Hellermann JP, Goraya TY, Jacobsen SJ, et al. Incidence of heart failure after myocardial infarction: is it changing over time?. Am J Epidemiol. 2003;157(12):1101–1107
  3. Spencer FA, Meyer TE, Goldberg RJ, et al. Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol. 1999;34(5):1378–1387
  4. Guidry UC, Evans JC, Larson MG, Wilson PW, Murabito JM, Levy D. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. Circulation. 1999;100(20):2054–2059
  5. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343(8893):311–322
  6. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease (I. Treatments following myocardial infarction). JAMA. 1988;260(14):2088–2093
  7. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331(7):417–424
  8. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy (Thrombolysis in Myocardial Infarction). J Am Coll Cardiol. 1998;31(7):1460–1465
  9. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease (FRISC Study Group. Fragmin during Instability in Coronary Artery Disease). N Engl J Med. 2000;343(16):1139–1147
  10. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105(15):1760–1763
  11. James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol. 2003;41(6):916–924
  12. Berton G, Cordiano R, Palmieri R, Pianca S, Pagliara V, Palatini P. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J. 2003;145(6):1094–1101
  13. Yip HK, Hang CL, Fang CY, et al. Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. Chest. 2005;127(3):803–808
  14. Suleiman M, Aronson D, Reisner SA, et al. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med. 2003;115(9):695–701
  15. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107(11):1486–1491
  16. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35(6):1628–1637
  17. Bodi V, Sanchis J, Llacer A, et al. Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST-elevation acute coronary syndromes. Am Heart J. 2005;149(2):268–274
  18. Pietila K, Harmoinen A, Hermens W, Simoons ML, Van de Werf F, Verstraete M. Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. Eur Heart J. 1993;14(7):915–919
  19. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis (CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial). J Am Coll Cardiol. 2000;35(6):1535–1542
  20. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71(3):266–274
  21. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003;108(20):2543–2549
  22. Prineas R, Crow R, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings. Littleton, MA: John Wright-PSG, Inc; 1982;
  23. Roger VL, Killian J, Henkel M, et al. Coronary disease surveillance in Olmsted County objectives and methodology. J Clin Epidemiol. 2002;55(6):593–601
  24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373–383
  25. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88(1):107–115
  26. Thom T, Haase N, Rosamond W, et al. Heart Disease and Stroke Statistics—2006 Update (A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee). Circulation. 2006;
  27. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695–706
  28. Abbate A, Biondi-Zoccai GG, Brugaletta S, Liuzzo G, Biasucci LM. C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes. Semin Vasc Med. 2003;3(4):375–384
  29. Lindsted KD, Fraser GE, Steinkohl M, Beeson WL. Healthy volunteer effect in a cohort study: temporal resolution in the Adventist health study. J Clin Epidemiol. 1996;49(7):783–790
  30. Gabriel AS, Martinsson A, Wretlind B, Ahnve S. IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. Eur J Intern Med. 2004;15(8):523–528
  31. Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol. 2006;47(5):962–968
  32. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91(11):988–998
  33. Knuefermann P, Vallejo J, Mann DL. The role of innate immune responses in the heart in health and disease. Trends Cardiovasc Med. 2004;14(1):1–7
  34. Zebrack JS, Anderson JL. Should C-reactive protein be measured routinely during acute myocardial infarction?. Am J Med. 2003;115(9):735–737
  35. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349(9050):462–466
  36. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112(10):1428–1434
  37. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190(12):1733–1740
  38. Barrett TD, Hennan JK, Marks RM, Lucchesi BR. C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther. 2002;303(3):1007–1013
  39. Steg PG, Ravaud P, Tedgui A, et al. Predischarge C-reactive protein and 1-year outcome after acute coronary syndromes. Am J Med. 2006;119:684–692
  40. Manginas A, Bei E, Chaidaroglou A, et al. Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I. Clin Cardiol. 2005;28(4):182–186
  41. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36(3):959–969Erratum in: J Am Coll Cardiol. 2001;37(3):973
  42. De Servi S, Mariani M, Mariani G, Mazzone A. C-reactive protein increase in unstable coronary disease cause or effect?. J Am Coll Cardiol. 2005;46(8):1496–1502
  43. Cusack MR, Marber MS, Lambiase PD, Bucknall CA, Redwood SR. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol. 2002;39(12):1917–1923
  44. Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006;114:201–208Epub 2006 Jul 10
  45. Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004;109(4):494–499
  46. Spencer FA, Meyer TE, Gore JM, Goldberg RJ. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction. Circulation. 2002;105(22):2605–2610
  47. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003;107(22):2786–2792
  48. Moller JE, Hillis GS, Oh JK, Reeder GS, Gersh BJ, Pellikka PA. Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction. Am Heart J. 2006;151(2):419–425
  49. Gibbons RJ, Valeti US, Araoz PA, Jaffe AS. The quantification of infarct size. J Am Coll Cardiol. 2004;44(8):1533–1542
  50. de Winter RJ, Fischer JC, de Jongh T, van Straalen JP, Bholasingh R, Sanders GT. Different time frames for the occurrence of elevated levels of cardiac troponin T and C-reactive protein in patients with acute myocardial infarction. Clin Chem Lab Med. 2000;38(11):1151–1153

 Supported in part by grants from the Public Health Service and the National Institutes of Health (AR30582, R01 HL 59205, R01 HL 72435) and by an American Heart Association Postdoctoral Greater Midwest Fellowship Award to Dr Bursi. Dr Roger is an Established Investigator of the American Heart Association.

PII: S0002-9343(06)01064-3

doi: 10.1016/j.amjmed.2006.07.039

The American Journal of Medicine
Volume 120, Issue 7 , Pages 616-622 , July 2007

Article Tools

* Image Usage & Resolution